HC Wainwright Issues Pessimistic Forecast for ARWR Earnings

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Stock analysts at HC Wainwright cut their FY2026 EPS estimates for Arrowhead Pharmaceuticals in a research note issued to investors on Thursday, January 23rd. HC Wainwright analyst P. Trucchio now forecasts that the biotechnology company will earn ($4.19) per share for the year, down from their previous forecast of ($3.96). HC Wainwright has a “Buy” rating and a $80.00 price target on the stock. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($3.40) per share. HC Wainwright also issued estimates for Arrowhead Pharmaceuticals’ FY2027 earnings at ($3.38) EPS, FY2028 earnings at ($3.40) EPS and FY2029 earnings at ($1.40) EPS.

ARWR has been the subject of several other reports. Citigroup lowered their price objective on Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Wednesday, November 27th. Sanford C. Bernstein lowered their price target on Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating for the company in a report on Friday, November 29th. StockNews.com raised Arrowhead Pharmaceuticals to a “sell” rating in a research report on Friday, December 20th. Piper Sandler decreased their price objective on shares of Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating for the company in a report on Wednesday, November 27th. Finally, Chardan Capital reissued a “buy” rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a report on Thursday, December 12th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, Arrowhead Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $43.33.

Arrowhead Pharmaceuticals Stock Performance

Shares of Arrowhead Pharmaceuticals stock opened at $20.25 on Monday. The company has a debt-to-equity ratio of 2.06, a quick ratio of 6.74 and a current ratio of 6.74. Arrowhead Pharmaceuticals has a 1 year low of $17.05 and a 1 year high of $36.72. The firm’s 50-day simple moving average is $20.76 and its 200-day simple moving average is $21.92. The firm has a market cap of $2.52 billion, a PE ratio of -4.03 and a beta of 0.97.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ARWR. State Street Corp raised its holdings in Arrowhead Pharmaceuticals by 8.8% during the third quarter. State Street Corp now owns 6,354,331 shares of the biotechnology company’s stock worth $123,083,000 after purchasing an additional 516,569 shares in the last quarter. Squarepoint Ops LLC acquired a new position in shares of Arrowhead Pharmaceuticals during the 2nd quarter valued at $9,976,000. Assenagon Asset Management S.A. raised its stake in shares of Arrowhead Pharmaceuticals by 232.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 293,083 shares of the biotechnology company’s stock worth $5,677,000 after buying an additional 204,933 shares in the last quarter. Millennium Management LLC lifted its holdings in shares of Arrowhead Pharmaceuticals by 61.9% in the second quarter. Millennium Management LLC now owns 529,251 shares of the biotechnology company’s stock valued at $13,755,000 after buying an additional 202,280 shares during the period. Finally, abrdn plc boosted its stake in Arrowhead Pharmaceuticals by 61.3% during the third quarter. abrdn plc now owns 401,146 shares of the biotechnology company’s stock valued at $7,770,000 after buying an additional 152,476 shares in the last quarter. 62.61% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Director William D. Waddill sold 3,748 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $21.90, for a total transaction of $82,081.20. Following the sale, the director now owns 44,125 shares of the company’s stock, valued at approximately $966,337.50. The trade was a 7.83 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Adeoye Y. Olukotun sold 2,850 shares of the business’s stock in a transaction that occurred on Friday, December 27th. The stock was sold at an average price of $20.00, for a total value of $57,000.00. Following the transaction, the director now owns 36,740 shares of the company’s stock, valued at approximately $734,800. This represents a 7.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 147,432 shares of company stock valued at $2,957,986. 4.50% of the stock is currently owned by company insiders.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.